Deutsche Bank
OBIO icon

Deutsche Bank’s Orchestra BioMed OBIO Stock Holding History

Deutsche Bank’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,219
Closed -$86.5K – 3693
2025
Q1 		$86.5K Buy
20,219
+8,134
+67% +$40.4K ﹤0.01% 3241
2024
Q4 		$48.3K Hold
12,085
– – ﹤0.01% 3416
2024
Q3 		$62.1K Buy
12,085
+6,002
+99% +$39.2K ﹤0.01% 3318
2024
Q2 		$49.6K Sell
6,083
-1,386
-19% -$8.03K ﹤0.01% 3328
2024
Q1 		$39.4K Sell
7,469
-315
-4% -$2.13K ﹤0.01% 3443
2023
Q4 		$71.1K Buy
+7,784
New +$53.1K ﹤0.01% 3355
2023
Q1 		– Sell
-15,041
Closed -$150K – 3957
2022
Q4 		$150K Hold
15,041
– – ﹤0.01% 3112
2022
Q3 		$149K Buy
+15,041
New +$149K ﹤0.01% 3121

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank's OBIO Position: Q2 2025 in Review

Deutsche Bank sold out of Orchestra BioMed (OBIO) in Q2 2025, closing a stake of 20,219 shares — an estimated $86.5K sold.

Deutsche Bank first reported a position in OBIO in Q3 2022 and held it in 8 quarters. The position peaked at $150K in Q4 2022. 59 funds tracked by Wall St. Rank hold OBIO as of Q2 2025.

  • Deutsche Bank reported no remaining Orchestra BioMed position as of Q2 2025 after selling out during the quarter.
  • Deutsche Bank sold 20,219 Orchestra BioMed shares in Q2 2025, an estimated $86.5K.
  • Deutsche Bank first reported a position in Orchestra BioMed in Q3 2022 and held it in 8 quarters.
  • Deutsche Bank's Orchestra BioMed position peaked at $150K in Q4 2022.
  • 59 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2025.

Based on Deutsche Bank's 13F filing for Q2 2025, filed 12 Aug 2025.